Quantifying benefit-risk preferences for new medicines in rare disease patients and caregivers by Morel, Thomas et al.
RESEARCH Open Access
Quantifying benefit-risk preferences for
new medicines in rare disease patients
and caregivers
T. Morel1*, S. Aymé2, D. Cassiman3, S. Simoens4, M. Morgan5 and M. Vandebroek6
Abstract
Background: Rare disease patients and caregivers face uncommon, serious, debilitating conditions often characterised
by poor prognosis and limited treatment options. This study aimed to explore what they consider of value when
choosing between hypothetical therapeutic options and to quantify both their benefit-risk preferences and the
influence of disease context.
Methods: A mixed-methods survey with patients and caregivers was conducted in the United Kingdom across a
range of rare diseases. Discrete-choice experiments that compared hypothetical treatment profiles of benefits and
risks were used to measure respondent preferences across a set of seven attributes related to health outcomes, safety,
and process of care. Bespoke questions on current disease management and the joint use of the 12-item WHODAS 2.0
questionnaire and of two Likert scales capturing self- and proxy-assessed disease-induced threat to life and impairment
were implemented to describe disease context. Additionally, qualitative insights on the definitions of value and risk
were collected from respondents.
Results: Final study sample included 721 patients and 152 informal caregivers, across 52 rare diseases. When choosing
between hypothetical novel treatments for rare diseases, respondents attributed most importance to drug response,
risk of serious side effects, and the ability to conduct usual activities while on treatment. In contrast, attributes related
to treatment modalities were the least important. Respondents expressed a willingness to accept risks in hopes of
finding some benefit, such as a higher chance of drug response or greater health improvement potential. Increasing
disease severity, impairment or disability, and the lack of effective therapeutic options were shown to raise significantly
the willingness to gain benefit through increased risk.
Conclusions: This is the first study performing a quantitative discrete choice experiment amongst patients and
caregivers across 52 rare conditions. It enables a more detailed understanding of the relationship between disease
context, treatment attributes and the degree of risk respondents are willing to take to gain a specific degree of benefit.
Researchers of novel therapeutics for rare diseases should be encouraged to invest in preference elicitation studies to
generate rigorous patient evidence and specific regulatory guidance should be issued to acknowledge their
importance and their use in marketing authorisations.
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Background
Regulatory decisions are typically depicted as a balancing
act between benefits and risks where both interpreta-
tions of hard clinical data and value judgements inter-
play. Traditionally, regulators have made assumptions,
albeit implicit, about what patients actually think and
prefer, including their willingness to trade benefits for
harms [1, 2]. Notwithstanding that the ultimate raison
d’être of any medicine is to benefit patients who have a
unique knowledge about their disease and its current
therapeutic environment, traditionally patient views and
preferences were rarely explicitly sought.
Recent developments, however, have suggested a cul-
ture shift is taking place as health care systems and
decision-makers have come to realise that the under-
standing of a disease and of the added value of new
medicines could not be fully achieved without engaging
with patients (and their caregivers). Roadmaps, processes
and tools to enhance patient involvement in drug devel-
opment [3, 4], medical decision-making [5–9], health
technology assessment [10], or drug licensing decisions
are now being debated. It still remains unclear, nonethe-
less, how the patient voice may formally be brought into
decision-making beyond anecdotal approaches (such as
including one patient on a committee or collecting a
handful of testimonials) and how rigorous patient evi-
dence may be generated to be readily accepted by
decision-makers. Acknowledging ‘the added value of
patients in benefit-risk considerations – in that they en-
rich regulatory decisions by complementing them with
the views of those directly affected by regulatory decisions’
[11], the European Medicines Agency (EMA) and the U.S.
Food and Drug Administration (FDA) have launched a
number of initiatives to start capturing patient views,
values and preferences to inform benefit-risk assessment
[12–16]. Their underlying objective has been to better
align acceptance of risks and uncertainties by regula-
tors with that of patients and with the interests of
public health more broadly. As the EMA stated, ‘an
excessive focus on avoiding risks and uncertainties
concerning new medicines might be against the inter-
ests of patients, delaying or reducing access to poten-
tially life-saving treatments’ [17].
Taking account of patients’ interests is of particular
significance when it comes to rare diseases which are
serious, debilitating conditions often characterised by
poor prognosis and limited treatment options. In this
context, rare disease patients and their representatives
have urged regulators to be more permissive and to
allow for drugs with greater risk or side effects than
traditionally accepted [2, 18–20]. For example, in its
draft guidance to the FDA the patient advocacy group
Parent Project Muscular Dystrophy stated that ‘in the
absence of any approved treatment for Duchenne at all
[…], the community [of Duchenne patients and families]
has expressed a willingness to accept a certain degree of
uncertainty regarding both benefit and risk. Some in the
community may be willing to take even greater risk – on
account of accelerated rates of progression, or their prox-
imity to loss of a vital function or death’ [19].
Adopting the perspective of the rare disease commu-
nity (while acknowledging its wide diversity across 7,000
rare diseases), the main purpose of the present study
was to contribute to the on-going discussion about what
patients affected by a rare disease and their caregivers
may consider ‘of value’ when considering new medicines
and to quantify their benefit-risk preferences. Under the
assumption that values and preferences are context-
dependent, our secondary research objectives were to
assess to what extent responder-reported assessments of
unmet need, disease severity and impairment influence
the value attached to key features (or attributes) of future
hypothetical treatments. This research used a discrete-
choice experiment to assess patient and caregiver prefer-
ences across a range of rare diseases.
Methods
Discrete-choice experiments
Discrete-choice experiments (DCE) have been used in-
creasingly in recent years to explore and quantify the
relative importance of the benefits and risks of different
treatments to patients and other stakeholders [21–30].
Well anchored in both psychology and economic theory
DCEs offer several advantages over simple rating or
ranking exercises, notably because they are shown to
give more reliable results [31, 32]. The main postulate of
DCEs is that treatments are composed of a set of fea-
tures, or ‘attributes’ and that the relative value of a par-
ticular treatment to an individual is a function of these
attributes [33–35]. DCEs can not only consider those
treatment attributes specifically related to health out-
comes such as efficacy and safety but also those that are
process related such as treatment duration, care location
or impact on caregivers. In a DCE, respondents are pre-
sented with a series of trade-offs in which they are
forced to state their preferences by choosing a preferred
alternative from a set of hypothetical treatment profiles.
These treatment profiles vary by ‘levels’ of treatment
attributes that may define the magnitude, severity, likeli-
hood, or timing of each. Statistical analysis of the
choices made reveals the implicit relative importance of
the attributes of the treatment. The result is an estimate
of the perceived value of a treatment as a weighted sum
of the treatment attributes.
Study sample
The design and implementation of this study relied on
a partnership with a sample of UK-based patient
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organisations and support groups, whose activity is
targeted at patients and families affected by rare dis-
eases. Eligible study partners were identified and re-
cruited through Orphanet UK’s network of patient
organisations. Study participants were subsequently
recruited from the study partners’ members list. Eli-
gible study participants were at least 18 years of age,
living in the United Kingdom, and were either individ-
uals affected by a rare disease or individuals acting as
informal caregivers to individuals affected by a rare
disease. Respondents who did not meet the inclusion
criteria were screened out. Respondents who did not
complete the survey or who always picked the first or
last alternative in a choice set were excluded from the
sample. Full details on study recruitment flow are
available in Additional file 1: Appendix A.
Patients and caregivers were informed that neither
benefits nor risks were derived by participating in this
study and provided informed consent. The information
sheet, consent form, and study protocol were reviewed
and approved by King’s College London’s Biomedical
Sciences, Dentistry, Medicine and Natural and Mathem-
atical Sciences Research Ethics Subcommittee. For each
completed and valid survey, a donation of £2 was made
to the participating patient organisations.
Survey instrument & experimental design
DCEs rely on survey instruments to elicit preferences.
A web-based survey, tailored to the two study target
audiences (i.e. patients, informal caregivers) was de-
veloped. While patients were invited to respond to
this survey in light of their own experience of the
disease and of their own values and preferences; care-
givers, in contrast, were requested to adopt a ‘proxy-
patient perspective’ [36] whereby they, as proxies,
were asked to respond as they think the patient they
usually provide informal care to would respond. The
survey had a similar structure for both study target
audiences and consisted of three successive modules.
In the first module, respondents had to describe their
experience with the disease (e.g. time since diagnosis,
current disease management, satisfaction with current
care etc.), and were subsequently invited to assess overall
disease severity. For this latter purpose we chose to im-
plement three alternative measurements: two Likert
scales (range 0–10) capturing self- and proxy-assessed
threat to life caused by the rare condition and disease-
induced impairment; and the 12-item World Health
Organization Disability Assessment Schedule 2.0 (WHO-
DAS 2.0). WHODAS 2.0 is a generic health and disability
assessment tool designed according to the International
Classification of Functioning, Disability, and Health (ICF)
framework [37, 38] [see Additional file 2: Appendix B and
Additional file 9: Appendix I].
The second survey module consisted of the DCE that
comprised a series of treatment-choice questions defined
by seven attributes: (1) ‘chance that the medicine will
work’, (2) ‘expected health improvement’, (3) ‘risk of ex-
periencing moderate side effects affecting quality of life’,
(4) ‘additional risk of getting serious side effects leading
to life-threatening consequences’, (5) ‘treatment duration’,
(6) ‘burden of treatment’, and (7) ‘ability to conduct usual
activities while on treatment’. Three levels were assigned
to each attribute [see Additional file 3: Appendix C for
details]. The choice of treatment attributes, definitions
and levels were informed by peer-reviewed scientific lit-
erature, patient advocacy literature, and consultation
with patients affected by a rare disease. Our design
choices were presented to representatives of the partici-
pating patient organisations for validation. Clinical ex-
perts also reviewed the choice of attribute levels to
ensure that they spanned the clinically relevant range of
outcomes that has been seen or may likely be seen in
clinical practice.
Attributes and levels were combined to create hypo-
thetical medication profiles. A D-efficient design was
generated with 40 choice sets in four orthogonal blocks,
each block containing 10 pairs of hypothetical medica-
tion profiles. Participants were then randomly assigned
to one of the four survey versions. Within each version,
the order of treatment choice questions was randomised
across participants. More information on the experimen-
tal design is included in Additional file 4: Appendix D.
During the DCE task, survey participants were asked to
point out which hypothetical medication profile in each
pair they would choose if the two treatments shown
were the only options available. Before completing it,
participants were presented with a detailed description
of all the attributes and levels by using pictures specific-
ally designed for this purpose in a user-friendly format.
Respondents were told to imagine that diagnosis had
just happened, that two alternative treatments existed,
and that they were in a position to influence the choice
of treatment. However, we confirmed that these treat-
ments do not currently exist and assured respondents
that this ‘was not a test’ and that there were ‘no right or
wrong answers’.
The third and last survey module included socio-
demographic questions and an open-text comment field
question where participants were invited to bring their
own definition of the ‘value of a medicine’.
A pilot study (June 17th–July 5th 2014; n: 68) across pa-
tients, patient representatives and other healthy volunteers
evaluated survey length, logic, skip patterns, trade-off com-
plexity, and wording. Survey length, flow, and language
were subsequently amended to address the feedback re-
ceived. An optional paper version of the survey was made
available to participating patient organisations where it was
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felt that the sole use of a web-based interface may intro-
duce a selection bias as a result of uneven access to/use of
Internet (e.g. lower income populations, elderly people).
Data analysis
Descriptive statistics were calculated for socio-
demographic, disease, and care management history
variables for all participants. The WHODAS total score
was calculated as the sum of the 12-item scores according
to the simple scoring instructions [38], with higher scores
reflecting greater disability. Summary scores on the re-
ported level of disease-induced impairment and threat to
life were analysed. Scores were generated for the variables
related to satisfaction with current care, current disease
management and impact of care on daily life across the
sub-group of participants who had reported on-going treat-
ment for the rare condition. An exploratory unmet need
score was derived by summing up the respective ratings of
these three variables.
Based on the trade-offs generated through the DCE, a
mixed logit model (or random parameter logit model)
was estimated with Hierarchical Bayes methodology
using the R-package bayesm. As highly flexible models,
mixed logit models are considered to be the state-of-
the-art discrete choice models [31, 32, 39–44]. They
allow to model the variation in preferences among the
respondents and yield not only estimates for the mean
preference and preference heterogeneity, but also indi-
vidual estimates representing the value that each re-
spondent attaches to the different attribute levels. They
are therefore best suited to investigate the relationship
between the individual preferences and various covari-
ates. The importance of each attribute was computed for
each respondent as the difference between the individual
part-worth estimate of the first (best) attribute level
minus the individual part-worth estimate for the last
(worst) attribute level (truncated below at zero if neces-
sary) and then rescaled by the sum to obtain the individ-
ual relative importance value for each attribute. Tests
for significance were performed on the individual part-
worths and relative importance for each attribute and
the robustness of these results was checked thoroughly
as explained in Additional file 5: Appendix E.
To evaluate whether the relative importance values are
influenced by the context of the disease – as captured by
respondents’ reported assessments on disease-induced im-
pairment, disability, threat to life, and overall unmet need
– a series of regression analyses where run where the indi-
vidual relative importance values for each attribute were
related to these measures in the total sample and different
subsamples to check the validity of the results.
Lastly, patients’ open-text comments on the ‘value of a
medicine’ were reviewed: statements were categorised in
terms of their specific focus and were then grouped into
broad themes.
Results
Study sample
The survey was administered between August and
November 2014 across 16 UK-based patient organisa-
tions – collectively representing over 80 rare/genetic
conditions – which had agreed to partner this research
project. At closure, the survey had yielded 1,160 re-
sponses and 893 participants qualified for the survey:
17.2 % had dropped out from the survey before
answering any trade-off question and 5.8 % did not
complete the trade-off module or survey. Twenty fur-
ther observations were excluded from the dataset after
internal validity checks showed that those respondents
had always selected either the first or last alternative
in each choice set [see Additional file 1: Appendix A
and Additional file 5: Appendix E for further details].
The profiles of respondents who were included and
excluded in the analysis were similar in terms of dis-
ease and socio-demographic characteristics.
After these exclusions, 873 respondents were available
for the final analysis: 721 patients (82.6 % of total
sample) and 152 informal caregivers (17.4 %), across a
total of 52 rare diseases. Additional file 6: Appendix F
presents summary statistics for the 873 respondents
included in the final analysis. Just over two-thirds of par-
ticipants were female (67.5 %), Caucasian (87.9 %) and
half the participants were aged between 35 and 54 years.
Overall, the three most represented groups of diseases
were: ‘rare systemic or rheumatological diseases’ (49.6 %),
‘rare neurologic diseases’ (19.0 %), and ‘inborn errors of me-
tabolism’ (17.9 %). Circa 70 % of respondents concentrated
across 10 rare diseases, namely: sarcoidosis (n:418), Fabry
disease (n:36), Duchenne muscular dystrophy (n:26), hypo-
pituitarism (n:26), transverse myelitis (n:26), amyotrophic
lateral sclerosis (n:24), Pompe disease (n:19), autosomal
dominant polycystic kidney disease (n:18), McArdle’s dis-
ease (n:16), and mucopolysaccharidosis I (n:16).
Over a third of the surveyed patients (36.5 %) had
been diagnosed over ten years ago and 70.7 % of patients
(n:510) reported being on treatment for their condition.
While 27.3 % of patients were employed full-time, a
similar proportion of patients declared being unable to
work due to disease-induced disability.
Caregivers were predominantly women (83.6 %) and
mostly cared for patients affected by inborn errors of
metabolism or rare neurologic diseases. 82.9 % (n:126)
of the patients they provide informal care to were re-
portedly under treatment. Within our sample, one out of
five caregivers had to stop working to provide informal
care. Whilst most caregivers were providing care as a
parent (63.8 %), they were almost equally split between
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caregivers to a child (48.7 %) and caregivers to an adult
(51.3 %). Nearly 40 % of them had been providing infor-
mal care for over ten years, and spending over 60 h per
week to perform that commitment.
The WHODAS 2.0 distribution of mean scores across
our study sample suggests clinically significant disability.
While the mean for the patient respondents was 16.6
(SD: 11.7, range 0–48) and that for the caregiver proxies
was 26.2 (SD: 13.4), it is noteworthy that only 5 % of
responding patients scored 0 – that is, reported no diffi-
culty in any activity. In contrast, 31 % (n:223) scored
above 24 and 6 % (n:46) above 36. Although there is no
agreed upon cut-off point for identifying individuals
with significant disability [45], scores ranging 24–35
and those above 36 are likely to represent moderate-to-
severe and severe-to-extreme disability respectively.
The fact that caregivers scored higher than patients
seems logical since most caregivers from our study
sample concentrate across some of the most debilitat-
ing conditions, such as Duchenne muscular dystrophy,
amyotrophic lateral sclerosis, or Sanfilippo disease [see
Additional file 6: Appendix F]. The other measurement
tool used in our survey related to impairment assess-
ment on a scale ranging 0–10 yielded a similar picture.
Of note, correlation between these two scales was
found to be 78.2 %.
When invited to assess their life expectancy compared
to that of other individuals of the same age and gender
but unaffected by the rare condition, 19 % of patients
(n:134) reported they would expect to live as long as
them; 11 % of patients (n:82), however, believed they
would have a ‘much shorter life’. The opposite was ob-
served from assessments from caregivers, as 51 % of
them were of the opinion that the patients they provide
informal care to would die earlier. The box-and-whisker
plots available in Additional file 6: Appendix F provide
further details on the distribution of the various assess-
ment scores used in this study.
As shown in Table 4 in Additional file 6: Appendix F, ca.
45 % of respondents declared being satisfied with current
care, with other 25 % being dissatisfied. Owing to the pau-
city of therapeutic alternatives to manage rare diseases,
only 10.6 % of participants reported an improvement in
health condition brought by current care or a cure from
the rare disease. Current disease management was re-
ported to result in: no improvement to health condition
(10.8 % of respondents); moderate survival extension
(8.3 %); improvements in quality of life (18.6 %); symptom
management (30 %); disease stabilisation (21.7 %).
Relative importance scores, preference weights & risk-
benefit trade-offs
Figure 1 presents for each attribute the mean relative
importance value and corresponding two-standard-error
interval. The most important attributes of a new medi-
cine for patients and caregivers across our study sam-
ple were: ‘the chance that the medicine will work’,
followed by ‘the risk of serious side effects’ and ‘the
ability to conduct usual activities while on treatment’
(which were both valued equally high), and the ‘ex-
pected health improvement’ that the medicine may
bring. The least important attributes proved to be
‘treatment duration’, followed by ‘burden of treatment’
– corresponding to two out of the three attributes re-
lating to process of care.
Figure 2 shows the estimated mean preference weight
(or part-worth) for each attribute level with the respect-
ive two-standard-error interval. The intervals did not
overlap, inferring that mean estimates can be considered
as statistically different between all the adjacent levels.
In general, preferences for the levels under each treat-
ment attribute were consistent with the a priori expect-
ation that levels with better outcomes, lower toxicity, or
lower care burden have higher preference weights (i.e.
they are more preferred) than levels corresponding to
worse outcomes, higher toxicity or greater care burden.
Please note that the absolute scale of the part-worths is
arbitrary; only relative differences across attributes and
attribute levels are meaningful.
This graph conveys several messages.
First, the difference between adjacent importance
weights indicates the relative importance of moving
from one level of an attribute to an adjacent level of that
attribute – the greater the distance, the greater the im-
portance attached to moving from one level to the next.
For instance, data suggested that, on average, respon-
dents attached a greater importance to moving from a
high risk to a moderate risk of serious side effects [see
change from l to k] than to reducing that risk from a
moderate to a low level [from k to j]. In contrast,
respondents assigned the same value to the opportunity
to shift from a monthly inpatient care setting to a
weekly outpatient care setting [r to q], as to moving
from weekly outpatient care to daily care delivery at
home [q to p] and vice-versa.
Second, and most importantly, the difference between
adjacent importance weights of one attribute can be
compared with the difference between adjacent import-
ance weights of another attribute – thus informing us
on possible trade-offs. On average, respondents were
willing to accept a 70 % increased risk of facing moder-
ate side effects [g to i] in exchange for a 35 % increased
chance to respond favourably to a new medicine [c to b].
Also, to get the opportunity to shift from a state of stabi-
lised disease to actual gains in overall functioning and
symptom alleviation [f to e], respondents showed a will-
ingness to accept a 20 % increase in the risk of moderate
side effects [g to h] or a 14 % increase in the risk of
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serious side effects [j to k]. Similarly, within the hypoth-
esis that they would be able to move away from a state
of improved functioning to a cure of the disease [e to d],
respondents would be ready to give up all of their ability
to conduct daily activities while on treatment [t to u], or
to face an increase in the risk of serious side effects from
15 to 30 % [k to l].
In summary, when considering the opportunity of a
new medicine targeting a rare condition, patients with
rare diseases and their caregivers stressed that they
attributed most importance to drug response, risk of
serious side effects, and the ability to conduct usual ac-
tivities while on treatment. However, our study sug-
gested that they were prepared to trade a significant
amount of risk associated with a new medicine for a
higher chance of drug response, or greater health im-
provement potential.
Effect of respondent-reported disease burden assessment
on attribute relative importance scores
A secondary objective of our study was to explore whether
‘disease context’, as measured by respondent-reported
assessments on disease-induced impairment, disability,
threat to life, satisfaction with current care, current disease
management and unmet need had an influence on the
relative importance of these attributes.
Figure 3 presents a summary of the regression analyses
investigating the effect of disease context on the relative
importance of the four attributes that were found earlier
as the most important to respondents. The magnitude
and direction of the estimated standardized effects are vi-
sualized either by an equals sign or by one or two arrows,
representing respectively the absence of effect, a small ef-
fect, or a large effect. Additional file 5: Appendix E pro-
vides more technical details on the statistical methods
followed and Additional file 7: Appendix G reports the
standardized regression coefficients and related statistics.
Within our study sample across 52 rare diseases, the
performed regression analyses described clear relation-
ship patterns between context of disease and attribute
relative importance. Data showed that as respondents
reported increasing impairment or disability, the value
attached to drug response and to health improvement
potential increased; in contrast, both the risk of serious
side effects and the ability to conduct usual activities
became less important to patients or their caregivers.
The same findings were observed as the rare disease be-
comes more life-threatening (with the exception of the
ability to conduct daily activities where no relationship
was found). Likewise, our data showed that expectations
for health improvement brought by a new medicine
increase as dissatisfaction with current treatment in-
creases. Lastly, the analysis concluded that the less
current disease management improves health condition,
the more one is ready to face the risk of serious side ef-
fects associated with a new medicine (i.e. the projected
value of this attribute decreases); and the more drug re-
sponse potential becomes important.
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An alternative analysis of the regression output – that
looked at how often statistical significance and observed
effect were found, instead of the observed size of the
standardized effect as reported above – yielded similar
conclusions. The outcome of this sensitivity analysis can
be found in Additional file 7: Appendix G. Of note, the
exploratory composite variable related to unmet need
proved insensitive to change (whilst its individual com-
ponents did) and is therefore not shown in Fig. 3. Details
on its statistical performance are available in Additional
file 5: Appendix E and Additional file 7: Appendix G.
Lastly, we also explored the presence of an effect of
disease context on the other three attributes included in
our study, namely ‘treatment duration’, ‘burden of treat-
ment’ and ‘risk of moderate side effects’ – that were
found the least important attributes for patients and
their caregivers. Hardly any effect was found from our
review, except to some extent on the attribute related to
burden of treatment.
In conclusion, our analysis quantified the influence of
disease context on rare disease patients’ and caregivers’
attitudes about benefit-risk. It provides evidence to sup-
port a widely shared assumption and a more detailed,
robust, understanding of the benefit-risk trade-offs that
respondents are ready to make, across different patient
populations and respondent types.
Patients’ open-text comments on ‘the value of a medicine’
Circa a third of survey participants took the opportunity
to comment at the end of the survey on their personal
experience of living with a rare disease, on their own
definition of value and on the survey itself. (Table 1)
displays a few excerpts from the qualitative feedback
collected from patients specifically. More quotations are
available in Additional file 8: Appendix H. Overall, five
main themes of comments emerged: hope, attitude to
risk, healthcare professionals, steroids use, and intro-
spection. All of these qualitative insights – stemming
from patients who have learnt to live with a poorly
understood, serious and progressing condition with lim-
ited treatment options – bring both real-life anchor and
colour to the quantitative data that our study generated.
Confronted with the ever approaching outcome of
disease progression, impairment or death, patients
made a compelling statement of ‘hope’: hope for new
medicines, hope for a halt to disease progression, hope
for symptom alleviation or partial recovery. In the con-
text of genetic diseases where a cure may reportedly be
impossible (at least within their life span), very few
patients stated being actually hopeful for a cure or full
recovery. This pragmatic stance balancing hope with
self-managed expectations may explain why survey re-
spondents during the quantitative trade-off scenarios
assigned a greater value to drug response potential than
to the actual magnitude of health improvement brought
by a new medicine.
A corollary to this ‘pragmatic hope’ is a willingness to
take risks. When weighing uncertain benefits brought by
a new medicine with unknown risks or outcomes, pa-
tients showed an articulate and informed attitude to risk
that they modulate according to their personal circum-
stances of disease seriousness, disease stage, or current
disease management. Whilst some patients declared hav-
ing ‘nothing to lose but everything to gain’ and thus be-
ing ready to face serious side effects, unknown outcomes
Table 1 Patients’ open-text comments on the ‘value of a
medicine’ (excerpts)
On hope
‘To have no hope is to have no life or anything to live for – any chance
[…] of not just a cure but hope that life will be longer or will not
deteriorate makes a difference beyond anything.’
‘Any new medicine that can give some hope to those suffering with such
diseases is invaluable.’
‘I would prefer research into new medicines [addressing my main
symptoms], rather than research into a ‘cure’ for my condition.’
‘We live in hope.’
‘Any port in the storm.’
On risk
‘With motor neurone disease any improvement outweighs any side
effects. Better to die than live with this cruel disease.’
‘We have nothing to lose but everything to gain.’
‘As I am symptom-free at present, I am against health risks. However,
once my condition deteriorates, my attitude to health risks will change.’
‘[Minor] side effects should not be underestimated or played down.
[They] can be extremely wearing and challenging when they occur every
day.’
‘I have discovered I am better off with no medicine, the side effects
made me feel worse.’
On interactions with healthcare professionals
‘Regular contact with health care professionals […] is invaluable.’
‘Doctors need to give us the information so we can decide for ourselves.’
‘Health professionals take a very ‘paternalistic’ stance and give minimum
information – “they know best”.’
‘Each new medicine should have the side effects explained in
percentages like this survey.’
‘Anything that engages the sufferer in discussions determining how to
handle treatment/medication can only be beneficial to the patient.’
On the impact of long-term use of steroids
‘[The medication] I object to most are steroids because of the physical
changes they have made to me. This side effect may not be as relevant/
important to other patients. This is an area the medical profession need
to be more sympathetic towards.’
‘Doctors prescribe [steroids] and do not explain the side effects and long
term effects and risks without discussing it with you or giving you the
options. They got me into remission after two years but I am still
suffering with other diseases caused by [steroids]. I would have opted for
other options if I was given a choice.’
Patients’ introspection
‘Really interesting survey, I learnt a lot about my attitude to risk.’
‘I found the survey quite thought provoking and made me think about
my current treatment plan and other options facing me.’
‘Answering the questions about value made me realise I regard the chance
of a beneficial effect as outweighing any possible risk or discomfort.’
Note: More patient quotations can be found in Additional file 8: Appendix H
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or even death in the hope that a treatment might offer
them some benefit, others stated being more reserved.
This correlation between risk readiness and disease con-
text expressed across these patient statements echoes
our quantitative findings shown in Figs. 2 and 3.
Patients also suggested an eagerness to be actively
involved in their own care and to become joint decision-
makers in treatment choices. They, however, report an
ambivalent relationship with their treating doctors and
other healthcare professionals. While ‘regular contact
with [doctors] is invaluable’, the latter may prove pater-
nalists and may not always listen to the patient’s feelings
or treatment preferences. ‘Doctors need to give us the
information so we can decide for ourselves’, some pa-
tients reported. The case of high-dose steroids use was
mentioned by a number of patients, where they felt they
had not been duly informed of their induced comorbidi-
ties at time of treatment decision.
Discussion
Rare diseases are poorly understood, serious, debilitat-
ing conditions often characterised by poor prognosis
and limited treatment options. Because patients and
caregivers constantly navigate the health care system in
search of disease management, they gradually gain an
intimate knowledge of the rare condition and are thus
in a position to identify when a treatment outcome be-
comes ‘meaningful’ to them and to subsequently articu-
late trade-offs.
Within the boundaries of our study, rare disease pa-
tients and their caregivers chose to adopt a realist view
and attributed the highest importance to drug response
potential, highlighting the importance of developing new
targeted therapies, diagnostic tests and expanding the
use of biomarkers [46–49] to better predict health bene-
fit. We may also interpret this finding as a result of
‘pragmatic hope’, as discussed earlier. Next, the other
two dimensions of highest value were the risk of serious
side effects and the ability to conduct usual activities
while on treatment. We consider the latter finding re-
garding patients’ activities compelling since it is usually
overlooked by researchers and clinicians who tend to
focus on the pathophysiological mechanisms and conse-
quences of a disease rather than on how the patient feels
and lives on a daily basis. In contrast, attributes related
to treatment modalities (i.e. how long, where and how to
take the medicine) were deemed the least important,
although the latter tend to be the focus of many drug
development programmes.
Additionally, our study data confirmed that patients
and their caregivers were willing to accept greater risk
or side effects associated with a new medicine, for in-
stance, in the hope for some extra chance in drug re-
sponse or greater health improvement potential. And, as
demonstrated by the outcome from the regression ana-
lyses performed, attitudes about benefit-risk may change
over time with disease progression or context of care.
Our findings are consistent with the analysis by social
scientists who defined risk as a ‘social construction’ ra-
ther than an objective and measurable function of the
probability and magnitude of an event [50, 51]. As
Douglas pointed out, ‘risk is not only the probability of
an event but also the probable magnitude of its outcome,
and everything depends on the value that is set on the
outcome. The evaluation is a political, aesthetic and
moral matter’ [52]. We may wish to add the word ‘con-
textual’ to that definition to bring in the dimensions of
unmet need and disease progression.
Overall, our research findings – which are reminiscent
of the work by Kesselheim [53] or Peay [54] – highlight
the need to systematically include patients in the process
of identifying meaningful treatment outcomes that
resonate with their experience, preferences, expectations
and values. As stated by Dr. Janet Woodcock from the
U.S. FDA ‘it is clear you have to start with an under-
standing of the impact of the disease on the people who
have it, and what they value most in terms of alleviation
before you set up a measurement and go forward with
truly patient-focused drug development’ [55].
In that context, we believe that patients and caregivers
should be increasingly involved as active research part-
ners in the development of clinical outcomes assess-
ments – including patient-reported outcomes (PRO)
measures – that directly evaluate how the patient feels,
functions or survives [56–58]. If a treatment effect is not
meaningful to the patient, it is not a benefit to the pa-
tient. Additionally, we believe that patient preference
data informing the development of those assessments
should be treated with the same level of scientific rigour
as currently with clinical data. Despite their different
focus, if guided by a clear hypothesis-led strategy, both
patient preference and PRO data offer complementary
evidence to substantiate label claims of ‘significant bene-
fit’ or ‘major contribution to patient care’. From that
perspective, researchers of novel therapeutics for rare
diseases should be encouraged to invest in the use of
such methods and specific regulatory guidance should
be issued to acknowledge their importance and to state
where these methods may fit into drug development
programmes and regulatory decision-making.
Patient-centred outcomes are key complements to trad-
itional clinical data that can purposefully help detect
meaningful and interpretable changes in health status and
treatment benefit. Efforts from the research community to
promote the development and use of patient-centred out-
come measures in rare diseases, such as the current work
by the International Rare Disease Research Consortium
(IRDiRC) are, in that context, promising [59].
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Limitations
This study includes a number of limitations; the four
main ones are discussed here. First, as a result of its am-
bition to review the preferences and values across over
50 rare conditions, the trade-offs module of our survey
applied non-disease-specific, generic attributes. This
limitation in the design of our study, however, was
reviewed and validated by our partners from the patient
organisations, and the survey was deemed appropriate
for use across different disease profiles. Second, our ana-
lysis relied on observations across a subset of rare dis-
eases – 52 of them – and an uneven number of patients
by disease, in part reflecting differences in prevalence.
Additionally, the diseases included in our study are very
different from each other and variations within each dis-
ease are also observed. The reality of that limitation was
acknowledged at time of study design and justified the
use of the three alternative self- / proxy-reported assess-
ment measurements to address it. In addition to the
individual estimates yielded from our DCE model, indi-
vidual differences in disease severity across the variety of
diseases were thus duly taken into account in our regres-
sion analyses. Third, our study sample is limited to
patients and caregivers living in the United Kingdom.
Since patient autonomy has become the dominant
principle shaping physician-patient relationships but
remains culture-dependent, our study results may not
apply as a proxy for patient preferences in another na-
tional healthcare setting. Fourth, our analysis relied on
the pooled data of patients’ and caregivers’ preferences:
comparative results between respondent types validated
that choice.
Conclusion
To the best of the authors’ knowledge, this study –
made possible thanks to the sustained commitment
from sixteen UK-based patient organisations – is the
first study performing a quantitative discrete choice
experiment amongst patients and their caregivers
across 52 rare conditions.
Conceptually anchored to the overarching goal of in-
corporating the patients’ perspectives into drug develop-
ment and approval processes, our study aimed to better
understand and quantify the preferences and values of
rare disease patients and families and to explore to what
extent the specific context of disease – such as disease-
induced disability or the perceived medical added-value
of currently available treatments – may alter these pref-
erences and values. This study offers an alternative ap-
proach to generate robust evidence about patients’
preferences and values from a wide range of patients
that can ultimately input to complete drug development
and approval decision-making processes.
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